P4HB and amyotrophic lateral sclerosis: The PDI detected in the compound’s target by eDRAC of both healthy and ALS patient fibroblast cells, appears to be interacting with other proteins in a similarly energy-dependent manner as previously described for the other assembly modulator compounds shown efficacious in other therapeutic areas [47,48].